SUMO4
Reaktivität: Human
WB, IHC, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Blot (1:1000) Immunohistochemistry (1:50-100) The optimal working dilution should be determined by the end user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
In PBS (0.09 % sodium azide)
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.
Park, Park, Kang, Yang, Kim: "Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes." in: Nature genetics, Vol. 37, Issue 2, pp. 112; author reply 112-3, (2005) (PubMed).
Bohren, Nadkarni, Song, Gabbay, Owerbach: "A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus." in: The Journal of biological chemistry, Vol. 279, Issue 26, pp. 27233-8, (2004) (PubMed).
Guo, Li, Zhang, Yang, Eckenrode, Hopkins, Zheng, Purohit, Podolsky, Muir, Wang, Dong, Brusko, Atkinson, Pozzilli, Zeidler, Raffel, Jacob, Park, Serrano-Rios, Larrad, Zhang, Garchon, Bach, Rotter, She et al.: "A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. ..." in: Nature genetics, Vol. 36, Issue 8, pp. 837-41, (2004) (PubMed).
Target
SUMO4
(Small Ubiquitin Related Modifier 4 (SUMO4))